Seino Yutaka
Kansai Electric Power Hospital , 2-1-7, Fukushima, Fukushima-ku, Osaka, JP 553-0003 , Japan +81 6 6458 5821 ;
Expert Opin Pharmacother. 2014 Dec;15(18):2741-9. doi: 10.1517/14656566.2014.978290. Epub 2014 Oct 30.
Sodium glucose cotransporter 2 (SGLT2) inhibitors are expected to provide adequate glycemic control, and be safe and well tolerated, for treating type 2 diabetes mellitus (T2DM). Luseogliflozin is a highly selective SGLT2 inhibitor that was recently approved for marketing and launched in Japan to treat T2DM.
This review summarizes the published data regarding the mechanism of action, clinical efficacy, and safety of luseogliflozin for treating T2DM. Other potential benefits of luseogliflozin, including lowering body weight and blood pressure, beyond its glucose-lowering effects are also discussed.
Luseogliflozin lowers plasma glucose concentration and body weight, and has beneficial effects on other clinically relevant parameters, including blood pressure and uric acid, in patients with T2DM. Although it had a good safety profile in clinical trials, there may be some safety concerns, including a possible decrease in muscle mass and an increase in ketone bodies. Therefore, careful administration and consideration of its benefit-risk balance are necessary. When using luseogliflozin, it is important to select appropriate patients and to adhere to its guidelines for use. If used correctly, luseogliflozin is expected to be positioned as a new type of oral hypoglycemic drug for treating T2DM.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂有望为2型糖尿病（T2DM）的治疗提供充分的血糖控制，且安全并具有良好的耐受性。鲁格列净是一种高度选择性的SGLT2抑制剂，最近已获批准上市并在日本推出用于治疗T2DM。
本综述总结了已发表的关于鲁格列净治疗T2DM的作用机制、临床疗效和安全性的数据。还讨论了鲁格列净除降血糖作用外的其他潜在益处，包括减轻体重和降低血压。
鲁格列净可降低T2DM患者的血浆葡萄糖浓度和体重，并对包括血压和尿酸在内的其他临床相关参数产生有益影响。尽管其在临床试验中具有良好的安全性，但可能存在一些安全问题，包括肌肉量可能减少和酮体增加。因此，需要谨慎用药并考虑其效益风险平衡。使用鲁格列净时，选择合适的患者并遵循其使用指南很重要。如果正确使用，鲁格列净有望成为治疗T2DM的新型口服降糖药物。
